Meet the Team
Our team's mission is to help extend the lives of patients battling metastatic cancer.
President and CEO
Dr. Christopher Mueller, Ph.D
Dr. Chris Mueller is a senior scientist and professor at the Cancer Research Institute at Queen's University in Kingston, Ontario. His research has involved studying epigenetics in different cancers, the relationship between stress and BRCA1, and developing methylation-based liquid biopsies. Chris earned his Ph.D (Microbiology and Immunology) from McGill University. He is involved in all aspects of company growth and has won various grants in advancing mDETECT to clinical validation.
​
Business Development Officer
Dr. Irsa Wiginton, Ph.D
Dr. Irsa (Shoukat) Wiginton is a trained scientist and passionate about translational medicine. She earned her M.Sc. and Ph.D. studying infectious human pathogens at Queen’s University and has successfully completed various certified business development and entrepreneurial training courses. She helps to lead business development activities including partnerships, commercialization and strategic growth initiatives to bridge the gap between academic innovation and clinical application.
​​
Scientific Officer
Keira Frosst
Keira Frosst is a dedicated scientist who has been fundamental in the development of the mDETECT tests. Her expertise in NGS-based liquid biopsies is instrumental and she plays a pivotal role in optimizing the assays for commercial sale. She also spearheads the clinical studies needed for validation. Keira has been the recipient of the prestigious Robert J. Wilson Fellowship and as completed top entrepreneurial acceleration programs, including Lab2Market, bridging molecular research with market-ready clinical tools.